Clinical research progress of ibrutinib in the treatment of chronic lymphocytic leukemia
10.3760/cma.j.issn.1008-6706.2019.14.035
- VernacularTitle: 伊布替尼治疗慢性淋巴细胞白血病临床研究进展
- Author:
Dongfeng MAO
1
;
Tao WU
;
Hai BAI
Author Information
1. Department of Hematology, Lanzhou General Hospital, Lanzhou Command, Lanzhou, Gansu 730050, China
- Publication Type:Journal Article
- Keywords:
Ibrutinib;
Leukemia, lymphocytic, chronic, B-cell;
B-Lymphocytes;
Tumor suppressor proteins;
Rituximab;
Fludarabine;
Cyclophosphamide;
Review
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(14):1789-1792
- CountryChina
- Language:Chinese
-
Abstract:
Chronic lymphocytic leukemia(CLL) is a heterogeneous mature B lymphocytic tumor.The apoptosis of mature lymphocyte is inhibited and clonal proliferation of mature lymphocyte aggregates in blood, bone marrow, spleen and lymph nodes, resulting in a class of inert hematological tumors.At present, the clinical pathogenesis is not completely clear, environmental and occupational factors do not occupy a major position.Studies have shown that long-term exposure to low-frequency electromagnetic fields may be associated with its incidence, but patients with primary and secondary relatives of lymphatic malignancies increased incidence.Many families still have patients whose age is earlier and the disease is more serious.In recent years, with the continuous improvement of medical level, a variety of treatment methods for chronic lymphoblastic leukemia have emerged, including a variety of new drugs.Ibutinib is the world's first marketed Bruton's tyrosine kinase(BTK) inhibitor, for more patients with chronic lymphoblastic leukemia has brought the gospel.This article reviews the clinical research progress of ibrutinib in treating CLL.
